



Virginia Commonwealth University
VCU Scholars Compass

Hepatobiliary Cancers: Pathobiology and
Translational Advances

Dept. of Pathology

2017

Identification of Common Molecular Subtypes of Asian Hepatocellular Carcinoma and Cholangiocarcinoma.

Anuradha Budhu

National Cancer Institute, Bethesda, United States, budhua@mail.nih.gov

Jittiporn Chaisaingmongkol

Chulabhorn Research Institute, Bangkok, Thailand, jittiporn@cri.or.th

Hien Dang

National Cancer Institute, Bethesda, United States, danghi@mail.nih.gov

See next page for additional authors

Follow this and additional works at: http://scholarscompass.vcu.edu/hepa_cancers

 Part of the [Medicine and Health Sciences Commons](#)

© The Author(s)

Downloaded from

http://scholarscompass.vcu.edu/hepa_cancers/30

This Abstract Accepted for Presentation is brought to you for free and open access by the Dept. of Pathology at VCU Scholars Compass. It has been accepted for inclusion in Hepatobiliary Cancers: Pathobiology and Translational Advances by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.

Authors

Anuradha Budhu, Jittiporn Chaisaingmongkol, Hien Dang, So Mee Kwon, Siritida Rabibhadana, Benjarath Pupacdi, Marshonna Forgues, Yosawat Pomyen, Vajarabhongsa Bhudhisawasdi, Nirush Lertprasertsuke, Anon Chotirosniramit, Chawalit Pairojkul, Chirayu Auewarakul, Thaniya Sricharunrat, Kannika Phornphutku, Suleeporn Sangrajrang, Maggie Cam, Ping He, Stephen M. Hewitt, Xiaolin Wu, Snorri S. Thorgeirsson, Paul S. Meltzer, Christopher Loffredo, Robert H. Wiltout, Curtis C. Harris, Chulabhorn Mahidol, Mathuros Ruchirawat, and Xin W. Wang

Identification of Common Molecular Subtypes of Asian Hepatocellular Carcinoma and Cholangiocarcinoma.

Anuradha Budhu¹, Jittiporn Chaisaingmongkol^{1,2}, Hien Dang¹, So Mee Kwon¹, Siritida Rabibhadana², Benjarath Pupacdi², Marshonna Forgues¹, Yotsawat Pomyen¹, Vajarabhongsa Bhudhisawasdi³, Nirush Lertprasertsuke⁴, Anon Chotirosniramit⁴, Chawalit Pairojkul³, Chirayu U. Auewarakul⁵, Thaniya Sricharunrat⁵, Kannika Phornphutkul⁶, Suleeporn Sangrajang⁷, Maggie Cam¹, Ping He⁸, Stephen M. Hewitt¹, Xiaolin Wu¹, Snorri S. Thorgeirsson¹, Paul S. Meltzer¹, Christopher A. Loffredo⁹, Robert H. Wiltout¹, Curtis C. Harris¹, Chulabhorn Mahidol², Mathuros Ruchirawat² and Xin Wei Wang¹

¹National Cancer Institute, Bethesda, United States; ²Chulabhorn Research Institute, Bangkok, Thailand; ³Khon Kaen University, Khon Kaen, Thailand; ⁴Chiang Mai University, Chiang Mai, Thailand; ⁵Chulabhorn Hospital, Bangkok, Thailand; ⁶Rajavej hospital and Lampang Cancer Center, Chiang Mai Thailand; ⁷National Cancer Institute, Bangkok, Thailand; and ⁸FDA, Bethesda, United States; ⁹Georgetown University Medical Center, Washington, DC, United States

Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) are clinically disparate primary liver cancers (PLC) with etiological and biological heterogeneity and are the primary cause of cancer mortality in Thailand. The Thailand Initiative in Genomics and Expression Research for Liver Cancer (TIGER-LC) consortium was established to identify genomic factors related to PLC risk, genetic susceptibility, and progression. We determined molecular subtypes among PLC patients by systematic integration of genomic, transcriptomic, and metabolic profiles. Genome wide profiling of 398 surgical specimens derived from 199 PLC patients was performed by Affymetrix HTA2.0 (transcriptome), Affymetrix Genome-Wide Human SNP Array 6.0 (somatic copy number alterations) and Metabolon's DiscoveryHD4 platform (metabolome). Unsupervised Consensus Clustering (cCluster), Subclass Mapping (SM), Gene Set Enrichment Analysis (GSEA), class comparison, loss of heterozygosity and minimum segmentation, Pearson and rank correlation algorithms were used to analyze and validate omics data in 852 Asian and Caucasian PLC cases. Thai HCC and ICC consisted of several stable molecular subtypes linked to similar prognosis that were validated in 247 Chinese HCC, 156 Asian American HCC and 182 Japanese ICC, but not in 163 European American HCC or 104 Caucasian ICC patients. While ICC and HCC share recurrently mutated genes, including *TP53*, *ARID1A*, and *ARID2*, mitotic checkpoint anomalies distinguish the C1 subtype with key drivers *PLK1* and *ECT2*, whereas the C2 subtype is linked to obesity, T-cell infiltration and bile acid metabolism. Thus, Asian ICC and HCC, while clinically treated as separate entities, share common molecular subtypes with similar actionable drivers to improve precision therapy.